Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

J. Remon; D. Isla; P. Garrido; J. de Castro; M. Majem; N. Viñolas; A. Artal; E. Carcereny; M. R. García-Campelo; P. Lianes; M. Provencio; O. Juan; P. Diz; R. Blanco; R. Lopez-Castro; I. Maestu; C. Vadell; E. Felip

doi:10.1007/s12094-017-1700-8

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

J. Remon, D. Isla, P. Garrido, J. de Castro, M. Majem, N. Viñolas, A. Artal, E. Carcereny, M. R. García-Campelo, P. Lianes, M. Provencio, O. Juan, P. Diz, R. Blanco, R. Lopez-Castro, I. Maestu, C. Vadell, E. Felip

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

4 Citations (Scopus)

Résumé

Background: The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer. Methods: WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis. Results: From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women. Conclusion: Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.

langue originale	Anglais
Pages (de - à)	1537-1542
Nombre de pages	6
journal	Clinical and Translational Oncology
Volume	19
Numéro de publication	12
Les DOIs	https://doi.org/10.1007/s12094-017-1700-8
état	Publié - 1 déc. 2017
Modification externe	Oui

Accès au document

10.1007/s12094-017-1700-8

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Remon, J., Isla, D., Garrido, P., de Castro, J., Majem, M., Viñolas, N., Artal, A., Carcereny, E., García-Campelo, M. R., Lianes, P., Provencio, M., Juan, O., Diz, P., Blanco, R., Lopez-Castro, R., Maestu, I., Vadell, C., & Felip, E. (2017). Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. Clinical and Translational Oncology, 19(12), 1537-1542. https://doi.org/10.1007/s12094-017-1700-8

@article{11552abaec4243c8bba68a62c0b498e9,

title = "Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database",

abstract = "Background: The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer. Methods: WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis. Results: From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women. Conclusion: Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.",

keywords = "Advanced, EGFR mutant, NSCLC, TKI, Women",

author = "J. Remon and D. Isla and P. Garrido and {de Castro}, J. and M. Majem and N. Vi{\~n}olas and A. Artal and E. Carcereny and Garc{\'i}a-Campelo, {M. R.} and P. Lianes and M. Provencio and O. Juan and P. Diz and R. Blanco and R. Lopez-Castro and I. Maestu and C. Vadell and E. Felip",

note = "Publisher Copyright: {\textcopyright} 2017, Federaci{\'o}n de Sociedades Espa{\~n}olas de Oncolog{\'i}a (FESEO).",

year = "2017",

month = dec,

day = "1",

doi = "10.1007/s12094-017-1700-8",

language = "English",

volume = "19",

pages = "1537--1542",

journal = "Clinical and Translational Oncology",

issn = "1699-048X",

number = "12",

}

Remon, J, Isla, D, Garrido, P, de Castro, J, Majem, M, Viñolas, N, Artal, A, Carcereny, E, García-Campelo, MR, Lianes, P, Provencio, M, Juan, O, Diz, P, Blanco, R, Lopez-Castro, R, Maestu, I, Vadell, C & Felip, E 2017, 'Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database', Clinical and Translational Oncology, VOL. 19, Numéro 12, p. 1537-1542. https://doi.org/10.1007/s12094-017-1700-8

TY - JOUR

T1 - Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting

T2 - the WORLD07 database

AU - Remon, J.

AU - Isla, D.

AU - Garrido, P.

AU - de Castro, J.

AU - Majem, M.

AU - Viñolas, N.

AU - Artal, A.

AU - Carcereny, E.

AU - García-Campelo, M. R.

AU - Lianes, P.

AU - Provencio, M.

AU - Juan, O.

AU - Diz, P.

AU - Blanco, R.

AU - Lopez-Castro, R.

AU - Maestu, I.

AU - Vadell, C.

AU - Felip, E.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background: The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer. Methods: WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis. Results: From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women. Conclusion: Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.

AB - Background: The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer. Methods: WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis. Results: From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women. Conclusion: Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.

KW - Advanced

KW - EGFR mutant

KW - NSCLC

KW - TKI

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=85025129845&partnerID=8YFLogxK

U2 - 10.1007/s12094-017-1700-8

DO - 10.1007/s12094-017-1700-8

M3 - Article

C2 - 28660482

AN - SCOPUS:85025129845

SN - 1699-048X

VL - 19

SP - 1537

EP - 1542

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

IS - 12

ER -